Skip to content

Late cardiac effects of anthracycline-based therapy in childhood cancer survivors: a CMR study of cardiac strain and function.

Aug 2026 · Clinical Research in Cardiology · 0 citations · 43 references
Medicine

TL;DR

A dose-dependent effect on subclinical cardiac function is suggested in childhood cancer survivors treated with anthracyclines, and incorporating CMR-FT strain assessment into the cardiac monitoring of CCS may help identify subclinical CTRCD in this population.

View source

Similar papers

Aug 2026

Right ventricular strain dynamics during anthracycline therapy in breast cancer patients stratified by cardiotoxicity risk: preliminary results

It is suggested that RV strain assessment provides information complementary to conventional LV–based cardiotoxicity criteria and may occur in the absence of concurrent changes in conventional LV cardiotoxicity parameters as currently defined.

Z. Tlegenova, A. Amanova, S. Balmagambetova et al. · 0 citations
Aug 2026

Beyond the left ventricle: right ventricular function as an early marker of cancer therapy related cardiac dysfunction

In this cohort of women treated with anthracyclines and anti-HER2 therapy, RV-FWLS identified patients who developed CTRCD, supporting RV strain as a useful tool for early risk stratification and refinement of cardio-oncology surveillance strategies.

B. Andrade, N. Cotrim, C. Coelho et al. · 0 citations
Open access Jul 2026

Age-Related Impairment of Left Atrial Phasic Strain in Childhood Cancer Survivors Treated with Anthracyclines.

Childhood cancer survivors (CCSs) are at increased risk of cancer therapy-related cardiac dysfunction following anthracycline chemotherapy. Although left atrial (LA) strain assessed by speckle-tracking echocardiography has emerged as a sensitive marker of diastolic dysfunction, it remains unclear when during survivorship LA dysfunction becomes detectable in CCSs treated with anthracyclines.In this retrospective observational case-control study, 92 CCSs (aged 4-32 years) and 96 age-matched healthy controls underwent echocardiography. Participants were stratified into three age groups (4-12, 13-18, and 19-32 years). LA reservoir, conduit, and pump strains were measured using two-dimensional speckle-tracking echocardiography from the apical four-chamber view. Conventional echocardiographic parameters, including mitral inflow velocities (E and A waves), E/A ratio, and tissue Doppler-derived e' and E/e', as well as left ventricular longitudinal strain (LVLS), were assessed.Conventional diastolic parameters did not significantly differ between CCSs and controls within corresponding age groups. However, in young adult CCSs (19-32 years), all three components of LA phasic strain (reservoir, conduit, and pump strains) were significantly reduced compared with age-matched controls. LVLS was also significantly lower in this group, whereas younger CCSs showed no significant differences in LA strain.LA phasic dysfunction was most evident in young adult CCSs despite preserved conventional diastolic indices, suggesting that age-stratified LA strain assessment may help identify survivorship stages at which atrial dysfunction becomes detectable.

Hiroyuki Sato, Ken Takahashi, Yumiko Hosono et al. · 0 citations
Review Open access Aug 2026

LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN FOR EARLY DETECTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN ADULT BREAST CANCER PATIENTS: A SYSTEMATIC REVIEW

LV GLS appears to be a sensitive and clinically useful echocardiographic marker for the early detection of anthracycline-induced cardiotoxicity in adult breast cancer patients and may improve identification of subclinical cardiac dysfunction before a measurable decline in left ventricular ejection fraction occurs.

T. Mainka, Emil Sergejuk, W. Kotlarski et al. · 0 citations
Open access Aug 2026

Cardiac monitoring and incidence of cardiotoxicity cardiomyopathy among breast cancer patients undergoing anthracycline regimen chemotherapy: insight from a single centre study

Anthracyclines remain a cornerstone of breast cancer therapy but carry a significant risk of cancer therapy-related cardiac dysfunction (CTRCD). This study evaluates the incidence of CTRCD in an Indonesian setting using the latest 2022 ESC Cardio-Oncology guidelines, focusing on subclinical markers such as high-sensitivity Troponin I (hs-cTnI), Global Longitudinal Strain (GLS) and Mechanical Dispersion (MD). This retrospective analytical cohort study involved 98 breast cancer patients treated with anthracyclines at a national referral hospital in Indonesia from July 2018 to February 2020. Clinical assessments, hs-cTnI, and echocardiography (LVEF, GLS, and MD) were performed at baseline, 1, 3, and 6 months. CTRCD was defined per the 2022 ESC criteria. CTRCD occurred in 74.5% of patients, predominantly as asymptomatic mild cases (63.26%). While symptomatic CTRCD was relatively low (7.14%), asymptomatic dysfunction was detected as early as one-month post-chemotherapy. A significant progressive decline was observed in LVEF (68.2 ± 6.2% to 61.3 ± 8.8%, p  < 0.001) and GLS (-19.7 ± 2.9% to -17.1 ± 3.5%, p  < 0.001). Notably, mechanical dispersion significantly increased over time ( p  = 0.029), and median hs-cTnI surged from 1.6 ng/L to 82.2 ng/L ( p  < 0.001) by month 6. The high incidence of asymptomatic CTRCD underscores the inadequacy of relying on clinical symptoms alone. Integration of hs-cTnI, GLS, and mechanical dispersion monitoring is may be essential for early detection and enables timely cardioprotective intervention.

Astri Astuti, Adila Aafiyah, Aurora Adila Arderia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.